SW
WST icon

SlateStone Wealth’s West Pharmaceutical WST Stock Holding History

SlateStone Wealth’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$901K Sell
2,510
-150
-6% -$45.9K 0.07% 176
2026
Q1 		$667K Buy
2,660
+195
+8% +$48.5K 0.06% 197
2025
Q4 		$678K Sell
2,465
-20
-0.8% -$5.47K 0.06% 194
2025
Q3 		$652K Hold
2,485
– – 0.06% 193
2025
Q2 		$544K Sell
2,485
-20
-0.8% -$4.28K 0.05% 204
2025
Q1 		$561K Buy
2,505
+415
+20% +$114K 0.06% 197
2024
Q4 		$685K Buy
2,090
+50
+2% +$15.7K 0.07% 181
2024
Q3 		$612K Hold
2,040
– – 0.06% 197
2024
Q2 		$672K Sell
2,040
-41
-2% -$14.5K 0.07% 181
2024
Q1 		$823K Buy
+2,081
New +$770K 0.08% 162

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SlateStone Wealth's WST Position: Q2 2026 in Review

SlateStone Wealth reduced its West Pharmaceutical (WST) stake by 5.6% in Q2 2026, selling an estimated $45.9K and leaving 2,510 shares worth $901K. The position accounts for 0.07% of the portfolio, ranked #176.

SlateStone Wealth first reported a position in WST in Q1 2024 and has held it in 10 quarters since. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • SlateStone Wealth held 2,510 shares of West Pharmaceutical worth $901K as of Q2 2026.
  • SlateStone Wealth sold 150 West Pharmaceutical shares in Q2 2026, an estimated $45.9K.
  • West Pharmaceutical made up 0.07% of SlateStone Wealth's portfolio in Q2 2026, its #176 holding.
  • SlateStone Wealth first reported a position in West Pharmaceutical in Q1 2024 and has held it in 10 quarters since.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on SlateStone Wealth's 13F filing for Q2 2026, filed 20 Jul 2026.